Virax Biolabs Group Ltd (VRAX) FinancialsVRAXVirax Biolabs Group Ltd

Evaluating the bottom line, Virax Biolabs Group Ltd maintains a gross margin of 80.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -160788.25%, while the net margin is -145725.93%. These profitability ratios, combined with a Return on Equity (ROE) of -80.87%, provide a clear picture of how effectively VRAX converts its operational activities into shareholder value.

In the context of the broader market, VRAX competes directly with industry leaders such as NXAT and GNLN. With a market capitalization of $938.00K, it holds a significant position in the sector. When comparing efficiency, VRAX's gross margin of 80.04% stands against NXAT's 8.81% and GNLN's 54.99%. Such benchmarking helps identify whether Virax Biolabs Group Ltd is trading at a premium or discount relative to its financial performance.

The financial performance of VRAX shows troubling signs, with a net income loss of -3,304,820 USD in Q1 2026 and a gross profit margin of -3381.20%, highlighting significant financial distress.